Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Free Cash Flow: 2020-2024

Historic Free Cash Flow for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to -$132.3 million.

  • Tango Therapeutics' Free Cash Flow rose 7.17% to -$31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$146.8 million, marking a year-over-year decrease of 19.15%. This contributed to the annual value of -$132.3 million for FY2024, which is 10.67% down from last year.
  • Per Tango Therapeutics' latest filing, its Free Cash Flow stood at -$132.3 million for FY2024, which was down 10.67% from -$119.5 million recorded in FY2023.
  • Tango Therapeutics' 5-year Free Cash Flow high stood at $69.0 million for FY2020, and its period low was -$132.3 million during FY2024.
  • Its 3-year average for Free Cash Flow is -$122.8 million, with a median of -$119.5 million in 2023.
  • Data for Tango Therapeutics' Free Cash Flow shows a maximum YoY plummeted of 188.97% (in 2021) over the last 5 years.
  • Over the past 5 years, Tango Therapeutics' Free Cash Flow (Yearly) stood at $69.0 million in 2020, then plummeted by 188.97% to -$61.4 million in 2021, then plummeted by 90.29% to -$116.8 million in 2022, then declined by 2.34% to -$119.5 million in 2023, then decreased by 10.67% to -$132.3 million in 2024.